CS419786A2 - Method of grippal vaccine production - Google Patents

Method of grippal vaccine production

Info

Publication number
CS419786A2
CS419786A2 CS864197A CS419786A CS419786A2 CS 419786 A2 CS419786 A2 CS 419786A2 CS 864197 A CS864197 A CS 864197A CS 419786 A CS419786 A CS 419786A CS 419786 A2 CS419786 A2 CS 419786A2
Authority
CS
Czechoslovakia
Prior art keywords
vaccine
complex
mdp derivative
particle
influenza
Prior art date
Application number
CS864197A
Other languages
English (en)
Other versions
CS269981B2 (en
Inventor
Kuniaki Nerome
Akira Oya
Kunio Ohkuma
Atsuo Inoue
Original Assignee
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Health filed Critical Nat Inst Health
Publication of CS419786A2 publication Critical patent/CS419786A2/cs
Publication of CS269981B2 publication Critical patent/CS269981B2/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5063Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068Cell membranes or bacterial membranes enclosing drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/5555Muramyl dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/829Liposomes, e.g. encapsulation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CS864197A 1985-06-06 1986-06-06 Method of grippal vaccine production CS269981B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60123341A JPH0688911B2 (ja) 1985-06-06 1985-06-06 インフルエンザワクチン及びその製造方法

Publications (2)

Publication Number Publication Date
CS419786A2 true CS419786A2 (en) 1989-04-14
CS269981B2 CS269981B2 (en) 1990-05-14

Family

ID=14858166

Family Applications (1)

Application Number Title Priority Date Filing Date
CS864197A CS269981B2 (en) 1985-06-06 1986-06-06 Method of grippal vaccine production

Country Status (12)

Country Link
US (1) US4826687A (cs)
EP (1) EP0205098B1 (cs)
JP (1) JPH0688911B2 (cs)
KR (1) KR940001373B1 (cs)
CN (1) CN1020407C (cs)
AT (1) ATE76756T1 (cs)
AU (1) AU585353B2 (cs)
CA (1) CA1262091A (cs)
CS (1) CS269981B2 (cs)
DE (1) DE3685519T2 (cs)
ES (1) ES8707113A1 (cs)
SU (1) SU1651782A3 (cs)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897873A (en) * 1984-04-12 1999-04-27 The Liposome Company, Inc. Affinity associated vaccine
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
WO1990001947A1 (en) * 1988-08-25 1990-03-08 The Liposome Company, Inc. Affinity associated vaccine
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
AU7239191A (en) * 1990-01-25 1991-08-21 University Of Colorado Foundation, Inc., The Method for preventing immune suppression in trauma patients
JP2777258B2 (ja) * 1990-03-13 1998-07-16 第一製薬株式会社 ムラミルジペプチド含有脂質膜構造体
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
NZ240369A (en) * 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
DE69533693T2 (de) * 1994-02-24 2005-12-22 Novavax Inc.(n.d.Ges.d.Staates Delaware) Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
ATE386506T1 (de) 1995-10-17 2008-03-15 Jagotec Ag Verabreichung unlöslicher arzneistoffe
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
DE69908304T2 (de) * 1998-02-11 2004-02-19 Rtp Pharma Corp. Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
IL143197A0 (en) * 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
EP1276465B1 (en) 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
JP4969761B2 (ja) 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
EP1320362B1 (en) * 2000-09-20 2011-08-31 Jagotec AG Stabilised fibrate microparticles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
EP2281573A3 (en) * 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB2386072A (en) * 2001-04-27 2003-09-10 Becton Dickinson Co Novel vaccine
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
CA2515779A1 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive method and compositions related to proteasomal interference
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
JP2007516968A (ja) * 2003-12-05 2007-06-28 ベクトン・ディキンソン・アンド・カンパニー 皮内コンパートメントにおける免疫応答を増強する方法、およびそれらの方法で有用な化合物
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US20090060889A1 (en) * 2007-03-12 2009-03-05 Von Hofe Eric Ii-RNAi involved Ii suppression in cancer immunotherapy
EP2278997B1 (en) 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsion influenza vaccine
EP2729169A1 (en) 2011-07-06 2014-05-14 Nanobio Corporation Human respiratory syncytial virus vaccine
JP6205360B2 (ja) 2011-08-22 2017-09-27 ナノバイオ コーポレーション 単純ヘルペスウイルスのナノエマルジョンワクチン

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009258A (en) * 1972-09-25 1977-02-22 The Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
CH589453A5 (cs) * 1974-01-14 1977-07-15 Sandoz Ag
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
DE3068743D1 (en) * 1980-01-16 1984-08-30 Weder Hans G Process and dialysis-installation for the preparation of bilayer-vesicles and their use
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4327182A (en) * 1981-01-22 1982-04-27 Connaught Laboratories Incorporated Purification of influenza sub-unit vaccine
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
FR2551758B1 (fr) * 1983-08-16 1986-01-31 Anvar Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages
IL69720A (en) * 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions

Also Published As

Publication number Publication date
AU5836586A (en) 1986-12-18
JPH0688911B2 (ja) 1994-11-09
US4826687A (en) 1989-05-02
ES555748A0 (es) 1987-07-01
DE3685519T2 (de) 1993-01-21
AU585353B2 (en) 1989-06-15
EP0205098A2 (en) 1986-12-17
EP0205098A3 (en) 1989-03-22
CS269981B2 (en) 1990-05-14
ATE76756T1 (de) 1992-06-15
CA1262091A (en) 1989-10-03
EP0205098B1 (en) 1992-06-03
CN86103717A (zh) 1987-02-11
CN1020407C (zh) 1993-05-05
KR870000075A (ko) 1987-02-16
DE3685519D1 (de) 1992-07-09
KR940001373B1 (ko) 1994-02-21
SU1651782A3 (ru) 1991-05-23
JPS61282321A (ja) 1986-12-12
ES8707113A1 (es) 1987-07-01

Similar Documents

Publication Publication Date Title
CS419786A2 (en) Method of grippal vaccine production
CA1279012C (en) Process for preparing immunogenic complexes and pharmaceutical composition containing these complexes
AU722647B2 (en) Protein-lipid vesicles and autogenous vaccine comprising the same
EP0047480B1 (en) Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
NO172727C (no) Fremgangsmaate for fremstilling av legemiddelholdige klorfluorcarbonaerosoldrivmiddelformuleringer
EP0335133A3 (en) Drug delivery using pulmonary surfactant fo facilitate absorption
DK55891D0 (da) Matrix med immunomodulerende virkning
Ribi et al. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins
AU1433788A (en) Natural pulmonary surfactant, method of preparation and pharmaceutical compositions
US5573779A (en) Liposome composition
CA2095627A1 (en) Stable lyophilized fatty emulsions and a process for the production thereof
ATE544470T1 (de) Immuntherapeutische methoden und zusammensetzungen
Alving et al. Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation
DE69023648D1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
CA2352563A1 (en) Method to produce inactivated w/o emulsion adjuvanted vaccines
DE68905613D1 (de) Pharmazeutische zubereitung.
EP0306912A3 (en) Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same.
AU6078399A (en) Ligand presenting assembly (lpa), method of preparation and uses thereof
BG51003A1 (en) Method for preparing of subunit liposome grippe vaccine
Bergers et al. Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice
SE8400934L (sv) Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner
ES2129342A1 (es) "formulacion de vacunas liposomales y su preparacion".
JPWO1993017702A1 (ja) 経口ワクチン